Product
Finerenone
Aliases
Finerenone (BAY94-8862), Finerenone (Kerendia, BAY94-8862)
Name
Kerendia
INN Name
finerenone
FDA Approved
Yes
24 clinical trials
1 organization
19 indications
1 document
Indication
chronic kidney diseaseIndication
Type 2 DiabetesIndication
Type 1 Diabetes MellitusIndication
ProteinuriaIndication
Chronic Kidney DiseaseIndication
Congestive Heart FailureIndication
Type 2 Diabetes MellitusIndication
ChildhoodIndication
Diabetic RetinopathyIndication
Primary AldosteronismIndication
Acute Heart FailureIndication
Cardiovascular DiseasesIndication
Type 1 DiabetesIndication
Kidney FailureIndication
Type 2 diabetesIndication
FinerenoneIndication
Mineralocorticoid Receptor AntagonistIndication
IgA NephropathyIndication
Safety IssuesClinical trial
Finerenone on Top of SGLT2is: A coMparatIve Hybrid Study Based oN RCT/RWE Data Of Patients With Chronic Kidney Disease Associated With Type 2 DiabetesStatus: Completed, Estimated PCD: 2023-12-20
Clinical trial
A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Addition to Standard of Care, in Participants With Chronic Kidney Disease and Type 1 DiabetesStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and ProteinuriaStatus: Recruiting, Estimated PCD: 2027-02-11
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of FInerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Patients With Non-Diabetic Chronic Kidney DiseaseStatus: Active (not recruiting), Estimated PCD: 2026-01-12
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%)Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Finerenone FIRST (Finerenone Research of Early Safety and Effectiveness), Part 2.0Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaStatus: Recruiting, Estimated PCD: 2028-08-11
Clinical trial
A Prospective, Interventional, Multicenter, Phase IV, Open-label, Single Arm Study to Assess the Safety and Effectiveness of Finerenone in Participants From India With Chronic Kidney Disease Associated With Type 2 Diabetes.Status: Recruiting, Estimated PCD: 2025-07-24
Clinical trial
FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 DiabetesStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD SubjectsStatus: Completed, Estimated PCD: 2021-12-31
Clinical trial
Finerenone Research of Outcomes and Drug UtilizationStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Clinical Trial Collecting Data From Routine Ophthalmological Examinations of Patients Who Were Randomized to Either Finerenone or Placebo in the Two Bayer-sponsored Phase 3 Clinical Trials FIDELIO-DKD and FIGARO-DKD to Investigate the Effect of Finerenone on Delaying the Progression of Diabetic RetinopathyStatus: Completed, Estimated PCD: 2021-06-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney DiseaseStatus: Completed, Estimated PCD: 2020-04-14
Clinical trial
A Double-blind, Randomized Controlled Study of Finerenone vs. Spironolactone in Hypertensive Patients With Primary AldosteronismStatus: Not yet recruiting, Estimated PCD: 2024-12-16
Clinical trial
Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesStatus: Not yet recruiting, Estimated PCD: 2029-02-01
Clinical trial
Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
Effects of Finerenone on Renal Hemodynamics and Oxidative StressStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)Status: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectStatus: Not yet recruiting, Estimated PCD: 2028-08-30
Clinical trial
Study on the Clinical Efficacy and Safety of the New Mineralocorticoid Receptor Antagonist Finerenone in the Treatment of Primary Aldosteronism: a Multicenter, Prospective, Open-label Clinical StudyStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Finerenone for Patients With Primary Aldosteronism (FAIRY): A Multicenter, Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGAStatus: Completed, Estimated PCD: 2024-03-31
Document
DailyMed Label: KerendiaOrganization
Bayer HealthCare Pharmaceuticals Inc.